布仑妥昔单抗维多汀
医学
无容量
苯达莫司汀
肿瘤科
内科学
不利影响
耐火材料(行星科学)
化疗
淋巴瘤
外科
免疫疗法
美罗华
CD30
癌症
物理
天体生物学
作者
Patrick Greve,Auke Beishuizen,Melanie M. Hagleitner,Jan Loeffen,Margreet A. Veening,Marianne Boes,Victor Peperzak,Claudius Diez,Friederike Meyer‐Wentrup
标识
DOI:10.3389/fimmu.2023.1229558
摘要
Introduction: Classical Hodgkin lymphoma (cHL) is the most common pediatric lymphoma. Approximately 10% of patients develop refractory or recurrent disease. These patients are treated with intensive chemotherapy followed by consolidation with radiotherapy or high-dose chemotherapy and autologous stem cell reinfusion. Although this treatment is effective, it comes at the cost of severe long-term adverse events, such as reduced fertility and an increased risk of secondary cancers. Recently, promising results of inducing remission with the immune checkpoint inhibitor nivolumab (targeting PD-1) and the anti-CD30 antibody-drug conjugate Brentuximab vedotin (BV) +/- bendamustine were published. Methods: Here we describe a cohort of 10 relapsed and refractory pediatric cHL patients treated with nivolumab + BV +/- bendamustine to induce remission prior to consolidation with standard treatment. Results and discussion: All patients achieved complete remission prior to consolidation treatment and are in ongoing complete remission with a median follow-up of 25 months (range: 12 to 42 months) after end-of-treatment. Only one adverse event of CTCAE grade 3 or higher due to nivolumab + BV was identified. Based on these results we conclude that immunotherapy with nivolumab + BV +/- bendamustine is an effective and safe treatment to induce remission in pediatric R/R cHL patients prior to standard consolidation treatment. We propose to evaluate this treatment further to study putative long-term toxicity and the possibility to reduce the intensity of consolidation treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI